Investigating How Childhood Tumours and Congenital Disease Develop
Launched by THE WELLCOME SANGER INSTITUTE · Sep 2, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Cancers and some congenital anomalies are caused by changes (mutations) in the genetic code (DNA) of cells. The use of Next Generation Sequencing (NGS) has enabled the study of the genetic changes that underpin these diseases, genome wide and at base pair resolution.
A key question about the molecular pathogenesis of a range of childhood tumours and congenital anomalies that remains unanswered is the order in which the different mutations arise. To define the order in which mutations arise, the investigators will need to reconstruct the life history of individual tumours / anomalies. This ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presence of childhood tumour / congenital disease, or relative of participant with childhood tumour / congenital disease
- • Sufficient \'surplus to diagnostic/clinical use\' tissue is available
- • Child assent and parental/guardian consent obtained where applicable
- Exclusion Criteria:
- • Insufficient surplus tissue is available
About The Wellcome Sanger Institute
The Wellcome Sanger Institute is a world-renowned genomics research center based in the UK, dedicated to advancing our understanding of human health and disease through cutting-edge genomic science. As a prominent sponsor of clinical trials, the institute leverages its expertise in genetics, bioinformatics, and large-scale data analysis to explore innovative therapeutic approaches and facilitate the translation of research findings into clinical applications. Committed to collaboration and excellence, the Wellcome Sanger Institute plays a pivotal role in the global biomedical research community, driving forward discoveries that have the potential to improve patient outcomes and transform healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, , United Kingdom
Patients applied
Trial Officials
Sam Behjati, PhD
Principal Investigator
The Wellcome Sanger Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported